| ASSET | QUARTER | % RETURN |
|---|---|---|
GT Biopharma (GTBP) | Q2 2015 | 1,778,503,896.82% |
Enveric Biosciences (ENVB) | Q2 2015 | 2,424.01% |
Cidara Therapeutics (CDTX) | Q2 2015 | 1,652.5% |
CleanSpark (CLSK) | Q2 2015 | 791.08% |
SurgePays (SURG) | Q2 2015 | 400% |
FiEE (FIEE) | Q2 2015 | 398.89% |
Marker Therapeutics (MRKR) | Q2 2015 | 357.14% |
Metalla Royalty & Streaming (MTA) | Q2 2015 | 200% |
Mawson Infrastructure (MIGI) | Q2 2015 | 171.43% |
YDKG (YDKG) | Q2 2015 | 145.45% |
Altisource Portfolio Solutions (ASPS) | Q2 2015 | 140.17% |
Tantech (TANH) | Q2 2015 | 135.62% |
Portage Biotech (PRTG) | Q2 2015 | 133.33% |
AlphaTON Capital (ATON) | Q2 2015 | 133.33% |
Natural Health Trend (NHTC) | Q2 2015 | 133.15% |
BIT Mining (BTCM) | Q2 2015 | 129.3% |
Celsius (CELH) | Q2 2015 | 126.37% |
Sarepta Therapeutics (SRPT) | Q2 2015 | 115.36% |
Galapagos NV ADR (GLPG) | Q2 2015 | 115.35% |
Heron Therapeuti (HRTX) | Q2 2015 | 115.34% |
Nomad Foods (NOMD) | Q2 2015 | 114.01% |
Digimarc (DMRC) | Q2 2015 | 105.74% |
Anavex Life Sciences (AVXL) | Q2 2015 | 105.48% |
Immutep Ltd ADR (IMMP) | Q2 2015 | 103.94% |
VerifyMe (VRME) | Q2 2015 | 101.74% |
